Table A3.
Adherence | Non-Hispanic Whites |
Hispanics |
||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Adherence rate | ||||||
≥ 95% | 1.0 | — | 1.0 | — | ||
94.9% to 90% | 2.8 | 0.2 to 45.7 | .46 | 5.6 | 1.5 to 21.2 | .01 |
89.9% to 85% | 13.6 | 1.2 to 154.1 | .03 | 2.4 | 0.4 to 13.5 | .33 |
< 85% | 30.9 | 3.3 to 286.9 | .003 | 3.1 | 0.9 to 10.9 | .08 |
Adherence rate | ||||||
≥ 95% | 1.0 | — | 1.0 | — | ||
< 95% | 11.6 | 1.4 to 96.5 | .02 | 3.3 | 1.1 to 9.8 | .03 |
NOTE. Adjusted for National Cancer Institute criteria of disease risk, sex, mercaptopurine dose-intensity, average parental education, annual household income, chromosomal abnormalities, and time from diagnosis to study entry.
Abbreviations: ALL, acute lymphoblastic leukemia; HR, hazard ratio.